Search bioRxiv⌕ Search

Biology subjects

Ran, S.

Publications and source records attributed to Ran, S..

2 recordsLinked to original sources

CHPF boosts proliferation and invasion of clear cell renal cell carcinoma

BackgroundClear cell renal cell carcinoma (ccRCC) is a malignant tumor most commonly seen in the urinary system, featuring quick progression, invasive behavior, frequent recrudesce, and bad prognosis, whereas Chondroitin polymerizing factor (CHPF) is an essential glycosyl transferase of biosynthesis involved chondroitin sulphate. But the relationship between the two has not been fully understood so far. The present research will probe into the relationship between CHPF and ccRCC. MethodsExplore the CHPF expression level in renal ccRCC tissues through bioinformatics analysis of The Cancer Genome Atlas (TCGA) and the real-time quantitative polymerase chain reaction detection system (qPCR); acquire relevant clinical data from the TCGA data-base and use Kaplan-Meier survival analysis to verify the relevance of CHPF expression to the clinical prognosis of ccRCC patients; then, effectively silence CHPF in ccRCC 786-O cells by a lentivirus-mediated approach; next, observe the effects of CHPF on tumor cell proliferation, cell cycle progression, and apoptosis. ResultsIn ccRCC tissues, CHPF expression has been significantly upregulated; the higher expression, the shorter survival of ccRCC patients. CHPF downregulation in the 786-O cell can effectively hold back the proliferation, apoptosis and cycle of cancer cells. ConclusionBased on the above results, we arrive at a conclusion that CHPF expression contributes markedly to the development of human ccRCC cells. Therefore, CHPF may act as a potential prognostic marker of ccRCC and provide a new target for ccRCC treatment. Simple SummaryChondroitin polymerizing factor (CHPF) is an important glycosyltransferase involved in the biosynthesis of chondroitin sulfate, which is thought to have some pro-carcinogenic effects. However, the role and mechanism of CHPF in clear cell renal cell carcinoma (ccRCC) have not been reported. The aim of this study was to investigate the relationship between CHPF and ccRCC. In this study, we found that CHPF was highly expressed in ccRCC and knocking out CHPF can greatly inhibit the proliferation and cell cycle progression of ccRCC and accelerate its apoptosis, suggesting that CHPF can predict the prognosis of ccRCC and a potential target for treatment.

genetics↗

Perfusable Apparatus For Thick-tissue Creation And Growth (patch) Of Cardiac Tissue

Cardiac tissue engineering has been developed as a potential alternative treatment for heart failure. However, current 3D tissues are limited in size and thickness due to the lack of an effective vascularization method. We have developed a novel bioreactor system to create viable vascularized cardiac tissue from multicellular spheroids using a digital light processing (DLP) 3D bioprinting system. Spheroids were created from induced pluripotent stem cells (iPSC) and cardiac fibroblasts (FB) using special dimple plates for mass production. One centimeter cubic tissues were created from spheroids using a DLP 3D printed mold with vascular channels. The tissue was maintained in a perfusion chamber under regulated flow and pressure following differentiation to cardiac tissue and endothelialization. Mass production of large spheroids (35,000 / tissue, diameter of 395.99 um +/- 101.15 um) was achieved from 170 million iPSCs and 50 million FBs for the creation of 1cm3 cardiac tissue in a 3D printed mold with vascular channels. The cardiac tissues (n=5) were perfused for 20 days under stable pressure of 17.5 +/- 3.05 PSI and flow of 5000 uL/min +/- 1116.42 uL/min. On days 10 and 20, Alamar blue assays showed viability for all five tissues (Alamar blue intensity: Day 10 1.57 +/- 0.15. Day 20 2.21 +/- 0.19). Thick and viable cardiac tissues were created and maintained using a 3D printed vascularized mold and perfusion system for maturation and growth in vitro for 30 days. This technology will open new doors for viable in vitro cardiac tissue creation.

bioengineering↗